Does OLAPARIB Cause Malignant neoplasm progression? 1,862 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,862 reports of Malignant neoplasm progression have been filed in association with OLAPARIB (Lynparza). This represents 10.2% of all adverse event reports for OLAPARIB.
1,862
Reports of Malignant neoplasm progression with OLAPARIB
10.2%
of all OLAPARIB reports
368
Deaths
180
Hospitalizations
How Dangerous Is Malignant neoplasm progression From OLAPARIB?
Of the 1,862 reports, 368 (19.8%) resulted in death, 180 (9.7%) required hospitalization, and 42 (2.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 1,862 reports have been filed with the FAERS database.
What Other Side Effects Does OLAPARIB Cause?
Death (4,378)
Nausea (1,582)
Anaemia (1,455)
Fatigue (1,437)
Off label use (777)
Vomiting (642)
Drug ineffective (563)
Diarrhoea (514)
Asthenia (491)
Myelodysplastic syndrome (466)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which OLAPARIB Alternatives Have Lower Malignant neoplasm progression Risk?
OLAPARIB vs OLARATUMAB
OLAPARIB vs OLECLUMAB
OLAPARIB vs OLIVE OIL\SOYBEAN OIL
OLAPARIB vs OLMESARTAN
OLAPARIB vs OLMESARTAN MEDOXOMIL